logo
  

Fox Corp. Q2 Adj. EBITDA Rises; Revenues Up 9%

Fox Corp. (FOXA,FOX) said it has once again delivered revenue and adjusted EBITDA growth in the second quarter, while continuing to invest in digital growth initiatives. Adjusted EBITDA was up 2% to $310 million, led by higher contributions at the Cable Network Programming segment. Also, the company has authorized a $4 billion stock repurchase program.

Second-quarter adjusted net income attributable to stockholders of $77 million or $0.13 per share compared to $93 million or $0.16 per share, a year ago. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.03, for the quarter. Analysts' estimates typically exclude special items.

Fox Corp. posted a net loss attributable to stockholders of $85 million or $0.15 per share compared to net income of $224 million or $0.37 per share, last year. The company noted that the variance was primarily due to the change in fair value of its investments recognized in Other, net.

Total revenues were $4.44 billion, a 9% increase from $4.09 billion, prior year. Analysts on average had estimated $4.27 billion in revenue.

Cable Network Programming reported segment revenues of $1.64 billion, an increase of 10% from last year. Television reported segment revenues of $2.76 billion, an increase of 8%.

The company has declared a dividend of $0.24 per Class A and Class B share. This dividend is payable on March 30, 2022 with a record date for determining dividend entitlements of March 2, 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT